Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Cowen & Co. Downgrades Graphite Bio to Market Perform

Cowen & Co. Downgrades Graphite Bio to Market Perform

Cowen & Co. analyst Phil Nadeau downgrades Graphite Bio (NASDAQ:GRPH) from Outperform to Market Perform.

byBenzinga Newsdesk

February 23, 2023

1 minute read

Cowen & Co. analyst Phil Nadeau downgrades Graphite Bio (NASDAQ:GRPH) from Outperform to Market Perform.

Earnings Scheduled For July 7, 2022

By Benzinga Insights

July 7, 6:55 AM

Companies Reporting Before The Bell • Northern Technologies (NASDAQ:NTIC) is likely to report quarterly earnings at $0.15 per share on revenue of $19.00 million.

BYRN

Jim Cramer Says AMD Under $150 Would Be ‘Terrific’ But ‘It Doesn’t Have What Nvidia Has’

By Benzinga Neuro

May 31, 7:04 AM

The semiconductor landscape has been witnessing intense competition, with Nvidia's dominance in the AI sector challenging rivals like AMD and Intel.

AMD

News
SEC

Ericsson Agreed With U.S. DOJ, SEC To Extend Term Of Co.’s Independent Compliance Monitor For One Year To June 2024

By Michael Horton

December 14, 5:03 PM

-Reuters

ERIC

FDA
News

Albireo Submits Bylvay Alagille Syndrome Regulatory Filings To FDA, EMA

By Benzinga Newsdesk

December 19, 9:33 AM

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low drug-related

ALBO

Cowen & Co. Downgrades Graphite Bio to Market Perform

Related Posts

Earnings Scheduled For July 7, 2022

Jim Cramer Says AMD Under $150 Would Be ‘Terrific’ But ‘It Doesn’t Have What Nvidia Has’

Ericsson Agreed With U.S. DOJ, SEC To Extend Term Of Co.’s Independent Compliance Monitor For One Year To June 2024

Albireo Submits Bylvay Alagille Syndrome Regulatory Filings To FDA, EMA